Screener
BioCryst Pharmaceuticals BCRX Tangible Asset Impairment Charges
Tangible Asset Impairment Charges at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:TangibleAssetImpairmentCharges.
The source filing: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:03 PM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-012240
| Line item | Years Ended December 31, 2025 | Years Ended December 31, 2024 | Years Ended December 31, 2023 |
|---|---|---|---|
| Non-cash interest expense on secured term loan and amortization of debt issuance costs | 1,387 | 11,638 | 15,447 |
| Amortization of discount on investments, net | (4,331) | (11,473) | (10,263) |
| Loss on extinguishment of debt | 17,332 | — | 29,019 |
| Loss on impairment | — | — | 1,548 |
| Gain on sale of non-financial asset | (550) | — | — |
| Gain on sale of BioCryst Ireland | (3,566) | — | — |
| Changes in operating assets and liabilities: | |||
| Increase in receivables | (36,806) | (22,698) | (6,095) |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is BioCryst Pharmaceuticals's tangible asset impairment charges?
- BioCryst Pharmaceuticals (BCRX) reported tangible asset impairment charges of $0 in Q4 2025.
- What does tangible asset impairment charges mean?
- Tangible Asset Impairment Charges
Ask your AI about BioCryst Pharmaceuticals's tangible asset impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude